Literature DB >> 1372581

Vitronectin in liver disorders: biochemical and immunohistochemical studies.

S Inuzuka1, T Ueno, T Torimura, S Tamaki, R Sakata, M Sata, H Yoshida, K Tanikawa.   

Abstract

The concentration of plasma vitronectin was determined and compared with various parameters of liver function including the blood coagulation system in patients with liver diseases. The severity of cirrhosis was graded according to Child's criteria and compared with the plasma vitronectin level. Furthermore, the distribution of vitronectin in the liver of patients with liver diseases was studied by light and electron microscopy using the indirect immunoperoxidase method. The plasma vitronectin level was low in all liver disease groups as compared with the healthy controls. The difference from the controls was significant in patients with hepatocellular carcinoma and decompensated cirrhosis. Moreover, the plasma vitronectin level was positively correlated with the levels of serum cholinesterase, albumin, plasma alpha 2 plasmin inhibitor-plasmin complex and the prothrombin time and results of the hepatoplastin test. Plasma vitronectin decreased with increasing severity of cirrhosis according to Child's criteria. These results suggest that the plasma vitronectin level is a useful parameter of hepatic synthetic function in patients with liver diseases; it may also reflect the severity of cirrhosis. Light microscopy revealed vitronectin in the area of focal necrosis and the portal tracts in the liver of patients with acute viral hepatitis, in the area of piecemeal necrosis in the liver of patients with chronic hepatitis and along the area of fiber deposition in the liver of patients with cirrhosis. Immunoelectron microscopy showed vitronectin in the rough endoplasmic reticulum of hepatocytes. Moreover, vitronectin was seen around inflammatory cells, endothelial cells, Ito cells and hepatocytes in the perisinusoidal area near focal necrosis and piecemeal necrosis and on collagen fibers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372581     DOI: 10.1002/hep.1840150413

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Vitronectin from brain pericytes promotes adult forebrain neurogenesis by stimulating CNTF.

Authors:  Cuihong Jia; Matthew P Keasey; Hannah M Malone; Chiharu Lovins; Richard R Sante; Vlad Razskazovskiy; Theo Hagg
Journal:  Exp Neurol       Date:  2018-11-06       Impact factor: 5.330

2.  Quantitation of vitronectin in serum: evaluation of its usefulness in routine clinical practice.

Authors:  N A Boyd; A R Bradwell; R A Thompson
Journal:  J Clin Pathol       Date:  1993-11       Impact factor: 3.411

3.  Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver.

Authors:  A Couvelard; J Y Scoazec; G Feldmann
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

4.  Development of glycoprotein capture-based label-free method for the high-throughput screening of differential glycoproteins in hepatocellular carcinoma.

Authors:  Rui Chen; Yexiong Tan; Min Wang; Fangjun Wang; Zhenzhen Yao; Liwei Dong; Mingliang Ye; Hongyang Wang; Hanfa Zou
Journal:  Mol Cell Proteomics       Date:  2011-04-07       Impact factor: 5.911

5.  Low levels of serum vitronectin associated with clinical phases in patients with hemorrhagic fever with renal syndrome.

Authors:  Zhengwen Liu; Qunying Han; Lei Zhang; Qianzi Zhao; Jinghong Chen; Sai Lou
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 3.984

6.  Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner.

Authors:  S Edwards; P F Lalor; C Tuncer; D H Adams
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

7.  Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH.

Authors:  Maria Del Ben; Diletta Overi; Licia Polimeni; Guido Carpino; Giancarlo Labbadia; Francesco Baratta; Daniele Pastori; Valeria Noce; Eugenio Gaudio; Francesco Angelico; Carmine Mancone
Journal:  Int J Mol Sci       Date:  2018-02-18       Impact factor: 5.923

8.  Screening of hepatocyte proteins binding with C‑terminally truncated surface antigen middle protein of hepatitis B virus (MHBst167) by a yeast two‑hybrid system.

Authors:  Zhi Qun Li; Enqiang Linghu; Wan Jun; Jun Cheng
Journal:  Mol Med Rep       Date:  2014-06-26       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.